Lipogen attained a U.S. patent for its phospholipid formulation targeting symptoms of premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD).
Photo © iStockphoto.com/VikaValter
Lipogen (Haifa, Israel) announced last week it has attained a U.S. patent for its phospholipid formulation targeting symptoms of premenstrual syndrome (PMS) and premenstrual dysphoric disoreder (PMDD).
The new patent for Lipogen’s phospholipid formulation is approved for “compositions and methods for alleviating symptoms associated with premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD).”
The patent comes after a recent study revealed a previously unrecognized PMS/PMDD benefit of Lipogen’s PS Plus ingredient.
“When the benefits of phospholipids on PMS and PMDD came to light through Lipogen’s research, we immediately explored its potential,” explains David Rutenberg, CEO, Lipogen. “Realizing the significance of this discovery, it encouraged us to further explore a product line for women’s health utilizing Lipogen’s proprietary phospholipid ingredients.”
The PMS/PMDD potential of Lipogen’s phospholipids first came to a light in a 2000-person study of Lipogen’s PS Plus ingredient for brain health and stress management. Out of 220 women under the age of 40 who consumed PS Plus regularly, 23 women (10.45%) reported relief of premenstrual syndromes, sleeping better, fewer mood swings, fewer hot flashes, and reduced stress.
“Based on these strong results, we improved the formulation and applied for a patent in the U.S. market,” says Rutenberg. He adds that Lipogen has also begun a double-blind, randomized, placebo-controlled clinical trial in Germany to learn more about the ways Lipogen’s formulation may help alleviate symptoms of PMS and PMDD.
Read more:
Lipogen Going after Stress-Management Market with Phospholipid Combo
Brain Health Dietary Supplements: This Is Your Brain on Phospholipids
Nutritional Ingredients for Women's Health
Michael Crane
Associate Editor
Nutritional Outlook Magazine
michael.crane@ubm.com
OmniActive partners with CRN to raise awareness about macular carotenoids for prenatal health
May 6th 2024OmniActive Health Technologies has announced a partnership with the Council for Responsible Nutrition to educate and raise awareness about the role of lutein and zeaxanthin in supporting maternal and fetal health during pregnancy among obstetricians, gynecologists, and other maternal healthcare practitioners.
What's next for NPA and CRN in their complaints against New York state?
May 2nd 2024The latest updates in the efforts of the Natural Products Association and the Council for Responsible Nutrition to sue New York state for its law banning the sale of weight management and muscle building supplements to minors.